<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36156207</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0404</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta neurologica Scandinavica</Title><ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation></Journal><ArticleTitle>Blood biomarkers in ALS: challenges, applications and novel frontiers.</ArticleTitle><Pagination><StartPage>375</StartPage><EndPage>388</EndPage><MedlinePgn>375-388</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ane.13698</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease among adults. With diagnosis reached relatively late into the disease process, extensive motor cell loss narrows the window for therapeutic opportunities. Clinical heterogeneity in ALS and the lack of disease-specific biomarkers have so far led to large-sized clinical trials with long follow-up needed to define clinical outcomes. In advanced ALS patients, there is presently limited scope to use imaging or invasive cerebrospinal fluid (CSF) collection as a source of disease biomarkers. The development of more patient-friendly and accessible blood biomarker assays is hampered by analytical hurdles like the matrix effect of blood components. However, blood also provides the opportunity to identify disease-specific adaptive changes of the stoichiometry and conformation of target proteins and the endogenous immunological response to low-abundance brain peptides, such as neurofilaments (Nf). Among those biomarkers under investigation in ALS, the change in concentration before or after diagnosis of Nf has been shown to aid prognostication and to allow the a priori stratification of ALS patients into smaller sized and clinically more homogeneous cohorts, supporting more affordable clinical trials. Here, we discuss the technical hurdles affecting reproducible and sensitive biomarker measurement in blood. We also summarize the state of the art of non-CSF biomarkers in the study of prognosis, disease progression, and treatment response. We will then address the potential as disease-specific biomarkers of the newly discovered cryptic peptides which are formed down-stream of TDP-43 loss of function, the hallmark of ALS pathobiology.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sturmey</LastName><ForeName>Ellie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre of Neuroscience, Surgery and Trauma, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre of Neuroscience, Surgery and Trauma, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Neurol Scand</MedlineTA><NlmUniqueID>0370336</NlmUniqueID><ISSNLinking>0001-6314</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood matrix effect</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">neurofilaments</Keyword><Keyword MajorTopicYN="N">pharmacodynamic biomarkers</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The Authors have no conflict of interest that would affect the publication of this article</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36156207</ArticleId><ArticleId IdType="pmc">PMC9828487</ArticleId><ArticleId IdType="doi">10.1111/ane.13698</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cook C, Petrucelli L. Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron. 2019;101(6):1057&#x2010;1069. doi:10.1016/j.neuron.2019.02.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.032</ArticleId><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2010;130. doi:10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2014;22(1):215&#x2010;218. doi:10.1111/ene.12421</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12421</ArticleId><ArticleId IdType="pubmed">24750431</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, Keren N, Kulka A, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016;87(12):1361&#x2010;1367. doi:10.1136/jnnp-2015-312908</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312908</ArticleId><ArticleId IdType="pmc">PMC5136716</ArticleId><ArticleId IdType="pubmed">27378085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in als and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2010;438. doi:10.1016/j.neuron.2013.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Shatunov A, Sproviero W, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140(6):1611&#x2010;1618. doi:10.1093/brain/awx082</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx082</ArticleId><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Dion PA, Rouleau GA. ALS: recent developments from genetics studies. Curr Neurol Neurosci Rep. 2016;16(6):59. doi:10.1007/s11910-016-0658-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-016-0658-1</ArticleId><ArticleId IdType="pubmed">27113253</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2010;206. doi:10.1038/nature20413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Maessen M, Veldink JH, Van Den Berg LH, Schouten HJ, Van Der Wal G, Onwuteaka&#x2010;Philipsen BD. Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients. J Neurol. 2010;257(7):1192&#x2010;1198. doi:10.1007/s00415-010-5474-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5474-y</ArticleId><ArticleId IdType="pubmed">20148336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1&#x2010;27. doi:10.3389/fnins.2019.01310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Couratier P, Blasco H, et al. Genetics of amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173:254&#x2010;262. doi:10.1007/s00115-013-3898-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00115-013-3898-1</ArticleId><ArticleId IdType="pubmed">28449881</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30(2):252&#x2010;258. doi:10.1007/s11825-018-0185-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11825-018-0185-3</ArticleId><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A&#x2010;L, Wilkins OG, Keuss MJ, et al. TDP&#x2010;43 loss and ALS&#x2010;risk SNPs drive mis&#x2010;splicing and depletion of UNC13A. Nature. 2022;603:131&#x2010;137. doi:10.1038/s41586-022-04436-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al&#x2010;Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975&#x2010;1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Diagnosing ALS: the Gold Coast criteria and the role of EMG. Pract Neurol. 2022;22:176&#x2010;178. doi:10.1136/practneurol-2021-003256</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2021-003256</ArticleId><ArticleId IdType="pmc">PMC9120398</ArticleId><ArticleId IdType="pubmed">34992096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D, Yang X, Wang Y, et al. The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population. Transl Neurodegener. 2021;10(1):2&#x2010;9. doi:10.1186/s40035-021-00253-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00253-2</ArticleId><ArticleId IdType="pmc">PMC8351337</ArticleId><ArticleId IdType="pubmed">34372918</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Martinez&#x2010;Lage P, Paquet C, et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016;12(2):154&#x2010;163. doi:10.1016/j.jalz.2015.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.08.003</ArticleId><ArticleId IdType="pubmed">26368321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro PM, Agosta F, Riva N, et al. Multimodal structural MRI in the diagnosis of motor neuron diseases. NeuroImage Clin. 2017;16:240&#x2010;247. doi:10.1016/j.nicl.2017.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC5545829</ArticleId><ArticleId IdType="pubmed">28794983</ArticleId></ArticleIdList></Reference><Reference><Citation>Manouchehrinia A, Piehl F, Hillert J, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7(1):139&#x2010;143. doi:10.1002/acn3.50972</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50972</ArticleId><ArticleId IdType="pmc">PMC6952306</ArticleId><ArticleId IdType="pubmed">31893563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmo J, Johnston DA, Dodart JC, et al. Peri&#x2010;arterial pathways for clearance of &#x3b1;&#x2010;synuclein and tau from the brain: implications for the pathogenesis of dementias and for immunotherapy. Alzheimer's Dement (Amst). 2020;12(1):1&#x2010;10. doi:10.1002/dad2.12070</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12070</ArticleId><ArticleId IdType="pmc">PMC7409108</ArticleId><ArticleId IdType="pubmed">32782922</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston SD, Steart PV, Wilkinson A, Nicoll JAR, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid &#x3b2; from the human brain. Neuropathol Appl Neurobiol. 2003;29(2):106&#x2010;117. doi:10.1046/j.1365-2990.2003.00424.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2990.2003.00424.x</ArticleId><ArticleId IdType="pubmed">12662319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, Gatherer M, Sharp MM, et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid&#x2010;&#x3b2; from the mouse brain. Aging Cell. 2013;12(2):224&#x2010;236. doi:10.1111/acel.12045</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12045</ArticleId><ArticleId IdType="pubmed">23413811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Lu CH, Cho Y, et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J Neurochem. 2018;146(5):631&#x2010;641. doi:10.1111/jnc.14542</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14542</ArticleId><ArticleId IdType="pmc">PMC6175430</ArticleId><ArticleId IdType="pubmed">29959860</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):59&#x2010;69. doi:10.1212/WNL.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Veeranna NRA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9(4):a018309. doi:10.1101/cshperspect.a018309</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a018309</ArticleId><ArticleId IdType="pmc">PMC5378049</ArticleId><ArticleId IdType="pubmed">28373358</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Logvinenko KB. Multiple fates of newly synthesized neurofilament proteins: evidence for a stationary neurofilament network distributed nonuniformly along axons of retinal ganglion cell neurons. J Cell Biol. 1986;102(2):647&#x2010;659. doi:10.1083/jcb.102.2.647</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.102.2.647</ArticleId><ArticleId IdType="pmc">PMC2114090</ArticleId><ArticleId IdType="pubmed">2418034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant HC. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem J. 1988;256(2):665&#x2010;668. doi:10.1042/bj2560665</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2560665</ArticleId><ArticleId IdType="pmc">PMC1135461</ArticleId><ArticleId IdType="pubmed">2851997</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Yuan A, Campbell J, Kumar A, Nixon RA. The C&#x2010;Terminal Domains of NF&#x2010;H and NF&#x2010;M Subunits Maintain Axonal Neurofilament Content by Blocking Turnover of the Stationary Neurofilament Network. PLoS One. 2012;7(9):1&#x2010;10. doi:10.1371/journal.pone.0044320</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044320</ArticleId><ArticleId IdType="pmc">PMC3448626</ArticleId><ArticleId IdType="pubmed">23028520</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Gowing G, Corti O, Mallet J, Julien JP. Conditional NF&#x2010;L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments. J Neurosci. 2007;27(18):4947&#x2010;4956. doi:10.1523/JNEUROSCI.5299-06.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5299-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672085</ArticleId><ArticleId IdType="pubmed">17475803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Tung VWY, Aghajanian J, Xu Z. Antagonistic roles of neurofilament subunits NF&#x2010;H and NF&#x2010;M against NF&#x2010;L in shaping dendritic arborization in spinal motor neurons. J Cell Biol. 1998;140(5):1167&#x2010;1176. doi:10.1083/jcb.140.5.1167</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.140.5.1167</ArticleId><ArticleId IdType="pmc">PMC2132708</ArticleId><ArticleId IdType="pubmed">9490729</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck R, Deek J, Safinya CR. Structures and interactions in &#x201c;bottlebrush&#x201d; neurofilaments: the role of charged disordered proteins in forming hydrogel networks. Biochem Soc Trans. 2012;40(5):1027&#x2010;1031. doi:10.1042/BST20120101</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120101</ArticleId><ArticleId IdType="pubmed">22988859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood G. &#x201c;Matrix effects&#x201d; in immunoassays. Scand J Clin Lab Invest. 1991;51:105&#x2010;112. doi:10.3109/00365519109104608</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365519109104608</ArticleId><ArticleId IdType="pubmed">1947738</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):1&#x2010;9. doi:10.1371/journal.pone.0075091</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament &#x201c;hook&#x201d; effect. J Neurosci Methods. 2011;195(2):143&#x2010;150. doi:10.1016/j.jneumeth.2010.11.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2010.11.026</ArticleId><ArticleId IdType="pubmed">21134399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86(5):565&#x2010;573. doi:10.1136/jnnp-2014-307672</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiutori R, Aarum J, Zubiri I, et al. The proteome of neurofilament&#x2010;containing protein aggregates in blood. Biochem Biophys Reports. 2018;14:168&#x2010;177. doi:10.1016/j.bbrep.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2018.04.010</ArticleId><ArticleId IdType="pmc">PMC5986704</ArticleId><ArticleId IdType="pubmed">29872749</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiutori R, Puentes F, Bremang M, et al. Analysis of circulating protein aggregates as a route of investigation into neurodegenerative disorders. Brain Commun. 2021;3(3):1&#x2010;16. doi:10.1093/braincomms/fcab148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab148</ArticleId><ArticleId IdType="pmc">PMC8361415</ArticleId><ArticleId IdType="pubmed">34396108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt AR, Yerbury JJ, Berghofer P, et al. Clusterin facilitates in vivo clearance of extracellular misfolded proteins. Cell Mol Life Sci. 2011;68(23):3919&#x2010;3931. doi:10.1007/s00018-011-0684-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-011-0684-8</ArticleId><ArticleId IdType="pubmed">21505792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury S, Keegan BM, Blagg BSJ. The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies. Med Res Rev. 2021;41(1):202&#x2010;222. doi:10.1002/med.21729</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21729</ArticleId><ArticleId IdType="pmc">PMC8485878</ArticleId><ArticleId IdType="pubmed">32844464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ, Mitchell JC, Novoselov S, et al. The heat shock response plays an important role in TDP&#x2010;43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. Brain. 2016;139(5):1417&#x2010;1432. doi:10.1093/brain/aww028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww028</ArticleId><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Pozzi S, Pignataro M, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10):e25545. doi:10.1371/journal.pone.0025545</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025545</ArticleId><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vats A, Gourie&#x2010;Devi M, Ahuja K, et al. Expression analysis of protein homeostasis pathways in the peripheral blood mononuclear cells of sporadic amyotrophic lateral sclerosis patients. J Neurol Sci. 2018;387:85&#x2010;91. doi:10.1016/j.jns.2018.01.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.01.035</ArticleId><ArticleId IdType="pubmed">29571878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of autoantibody&#x2010;induced pathology. Front Immunol. 2017;8:603. doi:10.3389/fimmu.2017.00603</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00603</ArticleId><ArticleId IdType="pmc">PMC5449453</ArticleId><ArticleId IdType="pubmed">28620373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, et al. Association of regulatory T&#x2010;cell expansion with progression of amyotrophic lateral sclerosis a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75(6):681&#x2010;689. doi:10.1001/jamaneurol.2018.0035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(5):1293&#x2010;1314. doi:10.1093/brain/awr074</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. Regulatory T&#x2010;lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO ssol Med. 2013;5(1):64&#x2010;79. doi:10.1002/emmm.201201544</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabinejad M, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, Rezaiemanesh A. Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: a clinical and preclinical systematic review. J Cell Physiol. 2020;235(6):5030&#x2010;5040. doi:10.1002/jcp.29401</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29401</ArticleId><ArticleId IdType="pubmed">31788795</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Lombardi V, Lu CH, et al. Humoral response to neurofilaments and dipeptide repeats in ALS progression. Ann Clin Transl Neurol. 2021;8:1831&#x2010;1844. doi:10.1002/acn3.51428</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51428</ArticleId><ArticleId IdType="pmc">PMC8419401</ArticleId><ArticleId IdType="pubmed">34318620</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen AK, Folke J, Owczarek S, et al. TDP&#x2010;43&#x2010;specific autoantibody decline in patients with amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):1&#x2010;12. doi:10.1212/NXI.0000000000000937</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000937</ArticleId><ArticleId IdType="pmc">PMC7768943</ArticleId><ArticleId IdType="pubmed">33361387</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SM, Khan G, Harris BT, Ravits J, Sierks MR. TDP&#x2010;43 protein variants as biomarkers in amyotrophic lateral sclerosis. BMC Neurosci. 2017;18(1):1&#x2010;12. doi:10.1186/s12868-017-0334-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0334-7</ArticleId><ArticleId IdType="pmc">PMC5264476</ArticleId><ArticleId IdType="pubmed">28122516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS One. 2017;12(7):1&#x2010;21. doi:10.1371/journal.pone.0182002</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 2017;74(6):677&#x2010;685. doi:10.1001/jamaneurol.2017.0357</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SH, Tian DY, Shen YY, et al. Amyloid&#x2010;beta uptake by blood monocytes is reduced with ageing and Alzheimer's disease. Transl Psychiatry. 2020;10(1):423. doi:10.1038/s41398-020-01113-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01113-9</ArticleId><ArticleId IdType="pmc">PMC7722845</ArticleId><ArticleId IdType="pubmed">33293506</ArticleId></ArticleIdList></Reference><Reference><Citation>Matharan M, Mathis S, Bonabaud S, Carla L, Soulages A, Le Masson G. Minimizing the diagnostic delay in amyotrophic lateral sclerosis: the role of nonneurologist practitioners. Neurol Res Int. 2020;2020:1&#x2010;8. doi:10.1155/2020/1473981</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1473981</ArticleId><ArticleId IdType="pmc">PMC7238340</ArticleId><ArticleId IdType="pubmed">32455015</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, Ryan P, Maguire S, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population&#x2010;based study of consultations, interventions and costs. PLoS One. 2017;12(6):1&#x2010;12. doi:10.1371/journal.pone.0179796</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179796</ArticleId><ArticleId IdType="pmc">PMC5480998</ArticleId><ArticleId IdType="pubmed">28640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J Neurol Sci. 2000;180(1&#x2013;2):76&#x2010;81. doi:10.1016/S0022-510X(00)00418-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00418-4</ArticleId><ArticleId IdType="pubmed">11090869</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Goossens J, De Meyer S, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol. 2019;6(10):1971&#x2010;1979. doi:10.1002/acn3.50890</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50890</ArticleId><ArticleId IdType="pmc">PMC6801162</ArticleId><ArticleId IdType="pubmed">31518073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O'Reilly EJ, Molsberry S, et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology. 2021;97(15):e1466&#x2010;e1474. doi:10.1212/wnl.0000000000012632</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000012632</ArticleId><ArticleId IdType="pmc">PMC8575132</ArticleId><ArticleId IdType="pubmed">34380747</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152&#x2010;158. doi:10.1002/ana.24552</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2010;2309. doi:10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2010;139. doi:10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. Neurofilaments in pre&#x2010;symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):538&#x2010;548. doi:10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(8):1296&#x2010;1306. doi:10.1002/acn3.51114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256(4):615&#x2010;619. doi:10.1007/s00415-009-0131-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0131-z</ArticleId><ArticleId IdType="pubmed">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157&#x2010;164. doi:10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2022;93(1):68&#x2010;74. doi:10.1136/jnnp-2021-327129</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327129</ArticleId><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A, Pujol&#x2010;Calder&#xf3;n F, Tjust AE, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021;11(1):22128. doi:10.1038/s41598-021-01499-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01499-6</ArticleId><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V, Mastrangelo A, Zenesini C, et al. Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross&#x2010;sectional and longitudinal study. Front Aging Neurosci. 2021;13:1&#x2010;11. doi:10.3389/fnagi.2021.753242</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.753242</ArticleId><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87(1):12&#x2010;20. doi:10.1136/jnnp-2015-311387</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE. PNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):146&#x2010;149. doi:10.3109/21678421.2012.729596</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.729596</ArticleId><ArticleId IdType="pubmed">23134506</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22&#x2010;e30. doi:10.1212/WNL.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnello L, Colletti T, Lo Sasso B, et al. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis. Eur J Neurol. 2021;28(6):1868&#x2010;1875. doi:10.1111/ene.14789</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14789</ArticleId><ArticleId IdType="pubmed">33638255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90(12):1338&#x2010;1346. doi:10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR. CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(11):1215&#x2010;1220. doi:10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xe4;ppe U, Chamoun S, Shen Q, et al. Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1&#x2013;2):58&#x2010;65. doi:10.1080/21678421.2021.1939384</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1939384</ArticleId><ArticleId IdType="pubmed">34151677</ArticleId></ArticleIdList></Reference><Reference><Citation>
Magen I, Coenen&#x2010;Stass A, Yacovzada NS, et al. Circulating miR&#x2010;181a&#x2010;5p is a prognostic biomarker for amyotrophic lateral sclerosis. BioRxiv. 2019;373426. https://www.nature.com/articles/s41593&#x2010;021&#x2010;00936&#x2010;z
</Citation><ArticleIdList><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, Mickunas M, Veyrune JL, et al. Repeated 5&#x2010;day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. EBioMedicine. 2020;59:102844. doi:10.1016/j.ebiom.2020.102844</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102844</ArticleId><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2010;220. doi:10.1016/S1474-4422(18)30394-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(3):274&#x2010;278. doi:10.1136/jnnp-2013-305494</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305494</ArticleId><ArticleId IdType="pubmed">24078718</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno&#x2010;Martinez L, Calvo AC, Mu&#xf1;oz MJ, Osta R. Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis? Int J Mol Sci. 2019;20(11):2759. doi:10.3390/ijms20112759</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112759</ArticleId><ArticleId IdType="pmc">PMC6600567</ArticleId><ArticleId IdType="pubmed">31195629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C&#x2010;H, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e244. doi:10.1212/nxi.0000000000000244</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Su WM, Cheng YF, Jiang Z, et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta&#x2010;analysis. EBioMedicine. 2021;74:103732. doi:10.1016/j.ebiom.2021.103732</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103732</ArticleId><ArticleId IdType="pmc">PMC8646173</ArticleId><ArticleId IdType="pubmed">34864363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2010;2257. doi:10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4(1):1&#x2010;11. doi:10.1093/braincomms/fcac029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7):748&#x2010;755. doi:10.1002/acn3.212</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291&#x2010;304. doi:10.1111/nan.12511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Pfluger C, Singh P, Lim CYH, Airey C, Henderson RD. Serial measurements of phosphorylated neurofilament&#x2010;heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. 2015;353(1&#x2013;2):122&#x2010;129. doi:10.1016/j.jns.2015.04.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.032</ArticleId><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2010;433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Li S, Chen S, et al. TDP&#x2010;43 and phosphorylated TDP&#x2010;43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis. Front Neurol. 2021;12:1&#x2010;8. doi:10.3389/fneur.2021.663637</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.663637</ArticleId><ArticleId IdType="pmc">PMC8236522</ArticleId><ArticleId IdType="pubmed">34194383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y, Kasai T, Noto YI, et al. Amyotrophic lateral sclerosis: correlations between fluid biomarkers of NfL, TDP&#x2010;43, and tau, and clinical characteristics. PLoS One. 2021;16(11):1&#x2010;13. doi:10.1371/journal.pone.0260323</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260323</ArticleId><ArticleId IdType="pmc">PMC8629269</ArticleId><ArticleId IdType="pubmed">34843548</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93(1):75&#x2010;81. doi:10.1136/jnnp-2021-327133</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327133</ArticleId><ArticleId IdType="pmc">PMC8685635</ArticleId><ArticleId IdType="pubmed">34518331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Carrero JJ, Zagai U, et al. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(11):2125&#x2010;2133. doi:10.1111/ene.14409</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M, Pozzilli V, Cambieri C, et al. Creatine kinase and progression rate in amyotrophic lateral sclerosis. Cell. 2020;9(5):1174. doi:10.3390/cells9051174</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="pubmed">32397320</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XP, Wei QQ, Ou RW, et al. Creatine kinase in the diagnosis and prognostic prediction of amyotrophic lateral sclerosis: a retrospective case&#x2010;control study. Neural Regen Res. 2021;16(3):591&#x2010;595. doi:10.4103/1673-5374.293159</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.293159</ArticleId><ArticleId IdType="pmc">PMC7996010</ArticleId><ArticleId IdType="pubmed">32985493</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo QF, Hu W, Xu LQ, Luo H, Wang N, Zhang QJ. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2021;8(2):448&#x2010;455. doi:10.1002/acn3.51299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51299</ArticleId><ArticleId IdType="pmc">PMC7886033</ArticleId><ArticleId IdType="pubmed">33449454</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg A, Skene N, Sanders F, et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27(4):640&#x2010;646. doi:10.1038/s41591-021-01295-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A. Theme 7 pre&#x2010;clinical therapeutic strategies. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:217&#x2010;245. doi:10.1080/21678421.2019.1646995</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646995</ArticleId><ArticleId IdType="pubmed">31702471</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz O, Schroth J, Lombardi V, et al. The expression of active CD11b monocytes in blood and disease progression in amyotrophic lateral sclerosis. Int J Mol Sci. 2022;23(6):3370. doi:10.3390/ijms23063370</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063370</ArticleId><ArticleId IdType="pmc">PMC8952310</ArticleId><ArticleId IdType="pubmed">35328793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Am Acad Neurol. 2017;12(88):1137&#x2010;1143. doi:10.1212/WNL.0000000000003741</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Karnaros V, Benyamin B, et al. Urinary neopterin: a novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(4):990&#x2010;999. doi:10.1111/ene.15237</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72&#x2010;associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(383):aai7866. doi:10.1126/scitranslmed.aai7866</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialov&#xe1; L, &#x160;varcov&#xe1; J, Bartos A, et al. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2010;17(4):562&#x2010;566. doi:10.1111/j.1468-1331.2009.02853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02853.x</ArticleId><ArticleId IdType="pubmed">19968709</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, van der Star BJ, Boomkamp SD, et al. Neurofilament light as an immune target for pathogenic antibodies. Immunology. 2017;152(4):580&#x2010;588. doi:10.1111/imm.12797</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12797</ArticleId><ArticleId IdType="pmc">PMC5680069</ArticleId><ArticleId IdType="pubmed">28718500</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, Domi T, Mandelli A, et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(7):1930&#x2010;1939. doi:10.1111/ene.15321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15321</ArticleId><ArticleId IdType="pmc">PMC9314044</ArticleId><ArticleId IdType="pubmed">35263489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2010;955. doi:10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:1&#x2010;28. doi:10.3389/fneur.2019.00291</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2010;748. doi:10.1002/med.21528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2010;119. doi:10.1056/nejmoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>
Biogen
. Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open&#x2010;Label Extension in SOD1&#x2010;ALS. 2021. Accessed 20 March 2022. http://media.biogen.com/news&#x2010;releases/news&#x2010;release&#x2010;details/biogen&#x2010;announces&#x2010;topline&#x2010;results&#x2010;tofersen&#x2010;phase&#x2010;3&#x2010;study&#x2010;and&#x2010;its
</Citation></Reference><Reference><Citation>
U.S. National Libary of Medicine
. A study to evaluate, safety, tolerability, pharmacodynamic (PD) markers and pharmacokinetics (PK) of AP&#x2010;101 in participants with amyotrophic lateral sclerosis (ALS). Clinical Trials .Gov. 2022. Accessed 20 March 2022. https://clinicaltrials.gov/ct2/show/NCT05039099
</Citation></Reference><Reference><Citation>Tran H, Moazami MP, Yang H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117&#x2010;124. doi:10.1038/s41591-021-01557-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson KM, Katona E, Glaria I, et al. Development of a sensitive trial&#x2010;ready poly(GP) CSF biomarker assay for C9orf72 &#x2010;associated frontotemporal dementia and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022. 0, 1&#x2010;11. doi:10.1136/jnnp-2021-328710</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328710</ArticleId><ArticleId IdType="pmc">PMC9279742</ArticleId><ArticleId IdType="pubmed">35379698</ArticleId></ArticleIdList></Reference><Reference><Citation>
Biogen
. Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis. 2022. Accessed 22 April 2022. https://investors.biogen.com/news&#x2010;releases/news&#x2010;release&#x2010;details/biogen&#x2010;and&#x2010;ionis&#x2010;announce&#x2010;topline&#x2010;phase&#x2010;1&#x2010;study&#x2010;results
</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate&#x2010;Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2010;930. doi:10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR. Tregs in ALS are dysfunctional and predict progression rate and severity. JCI Insight. 2017;2(5):1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, D'Amico R, Zucchi E, et al. Rapamycin treatment for amyotrophic lateral sclerosis protocol for a phase II randomized, double&#x2010;blind, placebo&#x2010;controlled, multicenter, clinical trial (RAP&#x2010;ALS trial). Medicine (Baltimore). 2018;97(24):e11119. doi:10.1097/MD.0000000000011119</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):242&#x2010;249. doi:10.1080/21678421.2017.1421666</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et al. TDP&#x2010;43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603:124&#x2010;130. doi:10.1038/s41586-022-04424-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>The ALSGEN Consortium . Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiol Aging. 2013;34(1):357.e7&#x2010;357.e19. doi:10.1016/j.neurobiolaging.2012.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.017</ArticleId><ArticleId IdType="pmc">PMC3839234</ArticleId><ArticleId IdType="pubmed">22959728</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Jiang H, Wang F, et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta&#x2010;analysis. Neurol Sci. 2019;40(11):2293&#x2010;2302. doi:10.1007/s10072-019-03951-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03951-y</ArticleId><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PWJ, van Rheenen W, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.e3&#x2010;630.e8. doi:10.1016/j.neurobiolaging.2011.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Baer GM, Elman L, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2019;73:190&#x2010;199. doi:10.1016/j.neurobiolaging.2018.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.031</ArticleId><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsu M, Hama Y, Utsumi J, et al. MicroRNA expression profiles of neuron&#x2010;derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci Lett. 2019;708(March):134176. doi:10.1016/j.neulet.2019.03.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.03.048</ArticleId><ArticleId IdType="pubmed">31173847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>